Last reviewed · How we verify
DWP14012 B mg
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes.
DWP14012 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | DWP14012 B mg |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DWP14012 works by inhibiting the DPP-4 enzyme, which normally breaks down incretin hormones (GLP-1 and GIP). By preventing this degradation, the drug increases circulating levels of these hormones, which stimulate insulin secretion in response to meals and suppress glucagon secretion, thereby lowering blood glucose levels. This mechanism is particularly effective in postprandial (after-meal) glucose control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers (PHASE1)
- Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects (PHASE1)
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects (PHASE1)
- Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |